Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 26;107(2):378–387. doi: 10.1002/cpt.1594

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 AbbVie Inc. Clinical Pharmacology & Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Relationships between risankizumab average plasma concentration (C _avg) and observed PASI90, PASI100, and sPGA0/1 responses at week 16 in the phase II trial. Note: C _avg represents average concentration from week 0 to 16. Median of C _avg (μg/mL): quartile 1 = 0.24 μg/mL, quartile 2 = 1.97 μg/mL, quartile 3 = 3.97 μg/mL, and quartile 4 = 7.88 μg/mL. PASI, Psoriasis Area and Severity Index; sPGA, static Physician's Global Assessment. [Colour figure can be viewed at http://wileyonlinelibrary.com]